CorMedix Inc. Announces Janet D. Dillione Will Join Board of Directors

CorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study

CorMedix Inc. to Join Russell Global and Russell 3000 Indexes

CorMedix Inc. Receives Positive Feedback from FDA for Neutrolin® Clinical Trial Protocol for Oncology Patients

CorMedix Presents Neutrolin® Post Marketing Surveillance Data at European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Conference

CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015

CorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences

CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore

CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants

CorMedix Clarifies Extension of Expiration Date for Publicly Traded Warrants

CorMedix Inc. Provides Multiple Strategic Business Updates

FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.’s Lead Product Candidate in the U.S.

CorMedix Inc. Receives Fast Track Designation For Neutrolin®